• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Michael S. Rogers, PhD


  • Rogers MS, Novak K, Zurakowski D, Cryan L, Blois A, Lifshits E, Bo TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN.Spontaneous Reversion of the Angiogenic Phenotype to a Non-angiogenic and Dormant State in Human Tumors.Mol Cancer Res. 2014 Feb 26.
  • Adini I, Ghosh K, Adini A, Chi ZL, Yoshimura T, Benny O, Connor KM, Rogers MS, Bazinet L, Birsner AE, Bielenberg DR, D'Amato RJ.Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment.J Clin Invest. 2014 Jan 2;124(1):425-36.
  • D'Amato RJ, Lentzsch S, Rogers MS.Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models.Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4818.
  • Cryan LM, Bazinet L, Habeshian KA, Cao S, Clardy J, Christensen KA, Rogers MS.1,2,3,4,6-Penta-O-galloyl-β-D-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2.J Med Chem. 2013 Mar 14;56(5):1940-5.
  • Cryan LM, Habeshian KA, Caldwell TP, Morris MT, Ackroyd PC, Christensen KA, Rogers MS.Identification of Small Molecules That Inhibit the Interaction of TEM8 with Anthrax Protective Antigen Using a FRET Assay.J Biomol Screen. 2013 Mar 11.
  • Rogers MS, Adini I, McBride AF, Birsner AE, D'Amato RJ.The albino mutation of tyrosinase alters ocular angiogenic responsiveness.Angiogenesis. 2013 Feb 20.
  • Rogers MS, D'Amato RJ.Common polymorphisms in angiogenesis.Cold Spring Harb Perspect Med. 2012;2(11).
  • Cao S, Cryan L, Habeshian KA, Murillo C, Tamayo-Castillo G, Rogers MS, Clardy J.Phenolic compounds as antiangiogenic CMG2 inhibitors from Costa Rican endophytic fungi.Bioorg Med Chem Lett. 2012 Sep 15;22(18):5885-8.
  • Rogers MS, Cryan LM, Habeshian KA, Bazinet L, Caldwell TP, Ackroyd PC, Christensen KA.A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.PLoS ONE. 2012;7(6):e39911.
  • Cryan LM, Rogers MS.Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy.Front Biosci. 2011;16:1574-88. Review.
  • Nakai K, Rogers MS, Baba T, Funakoshi T, Birsner AE, Luyindula DS, D'Amato RJ.Genetic loci that control the size of laser-induced choroidal neovascularization.FASEB J. 2009 Jul;23(7):2235-43.
  • Rogers MS, Birsner AE, D'Amato RJ.The mouse cornea micropocket angiogenesis assay.Nat Protoc. 2007;2(10):2545-50.
  • Rogers MS, Christensen KA, Birsner AE, Short SM, Wigelsworth DJ, Collier RJ, D'Amato RJ.Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth.Cancer Res. 2007 Oct 15;67(20):9980-5.
  • Folkman J, Rogers MS.Thalidomide for multiple myeloma.N Engl J Med. 2006 Jun 1;354(22):2389-90; author reply 2389-90.
  • Rogers MS, D'Amato RJ.The effect of genetic diversity on angiogenesis.Exp Cell Res. 2006 Mar 10;312(5):561-74. Review.
  • Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS.Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.Cancer Cell. 2005 Jan;7(1):101-11.
  • Rogers MS, Rohan RM, Birsner AE, D'Amato RJ.Genetic loci that control the angiogenic response to basic fibroblast growth factor.FASEB J. 2004 Jul;18(10):1050-9.
  • Rogers MS, Rohan RM, Birsner AE, D'Amato RJ.Genetic loci that control vascular endothelial growth factor-induced angiogenesis.FASEB J. 2003 Nov;17(14):2112-4.
  • Browder T, Folkman J, Hahnfeldt P, Heymach J, Hlatky L, Kieran M, Rogers MS.Antiangiogenic therapy and p53.Science. 2002 Jul 26;297(5581):471; discussion 471.
  • Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D'Amato RJ.S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.Cancer Res. 2002 Apr 15;62(8):2300-5.